Weixiang Lu
Impact in
- Oncology top 1%
- COVID-19 and healthcare impacts
- Cancer survivorship and care
- Infectious Diseases top 1%
- COVID-19 Clinical Research Studies
- SARS-CoV-2 and COVID-19 Research
Papers in
-
- Lung Cancer Diagnosis and Treatment 4
- Ferroptosis and cancer prognosis 2
- Lung Cancer Treatments and Mutations 2
- Oncology 6
- CAR-T cell therapy research 2
- Co-authors
- Jianfu Li (4 shared papers)Jianxing He (6 shared papers)Wenhua Liang (4 shared papers)Ke Xu (2 shared papers)Hengrui Liang (3 shared papers)Caichen Li (3 shared papers)Qing Ai (2 shared papers)Wei Wang (1 shared paper)
- Journals
- Annals of Hematology (2 papers)Journal for ImmunoTherapy of Cancer (2 papers)BJS Open (1 paper)Annals of Palliative Medicine (1 paper)Advanced Science (1 paper)
- Partner nations
- ChinaUnited States
In The Last Decade
Weixiang Lu
16 papers receiving 2.9k citations
Weixiang Lu's Hit Papers
Peers
Comparison fields: 5 of 107
- Oncology 2.3k
- Infectious Diseases 1.3k
- Neurology 261
- Radiology, Nuclear Medicine and Imaging 361
- Obstetrics and Gynecology 118
Countries citing papers authored by Weixiang Lu
This map shows the geographic impact of Weixiang Lu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Weixiang Lu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Weixiang Lu more than expected).
Fields of papers citing papers by Weixiang Lu
This network shows the impact of papers produced by Weixiang Lu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Weixiang Lu. The network helps show where Weixiang Lu may publish in the future.
Co-authors
The 25 scholars most cited alongside Weixiang Lu, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China Hit paper breakdown → | 2020 | 2867 |
| 2 | 2021 | 41 | |
| 3 | 2021 | 8 | |
| 4 | 2023 | 5 | |
| 5 | 2021 | 5 | |
| 6 | 2024 | 4 | |
| 7 | 2021 | 4 | |
| 8 | 2024 | 4 | |
| 9 | 2025 | 3 | |
| 10 | 2023 | 2 | |
| 11 | 2022 | 2 | |
| 12 | 2024 | 1 | |
| 13 | 2024 | 1 | |
| 14 | 2023 | 1 | |
| 15 | 2024 | 1 | |
| 16 | 2012 | 1 | |
| 17 | 2023 | 0 | |
| 18 | 2025 | 0 | |
| 19 | 2025 | 0 |
About Weixiang Lu
Weixiang Lu is a scholar working on Pulmonary and Respiratory Medicine, Oncology, Immunology, Surgery and Molecular Biology, having authored 19 papers that have together received 3.0k indexed citations. Recurring topics across this work include Lung Cancer Diagnosis and Treatment (4 papers), Acute Myeloid Leukemia Research (2 papers), CAR-T cell therapy research (2 papers), Ferroptosis and cancer prognosis (2 papers), Biosimilars and Bioanalytical Methods (2 papers), Lymphoma Diagnosis and Treatment (2 papers), Lung Cancer Treatments and Mutations (2 papers) and Monoclonal and Polyclonal Antibodies Research (2 papers). The work is most often cited by research in Oncology (2.3k citations), Infectious Diseases (1.3k citations), Neurology (261 citations), Radiology, Nuclear Medicine and Imaging (361 citations) and Obstetrics and Gynecology (118 citations). Weixiang Lu has collaborated with scholars based in China and United States. Frequent co-authors include Jianfu Li, Jianxing He, Wenhua Liang, Ke Xu, Hengrui Liang, Caichen Li, Qing Ai, Wei Wang, Wei‐jie Guan and Shiyue Li. Their work appears in journals such as Annals of Hematology, Journal for ImmunoTherapy of Cancer, BJS Open, Annals of Palliative Medicine and Advanced Science.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.